BMS-Celgene Merger: Worth It?

In January, Bristol-Myers Squibb (BMS) announced that they would acquire Celgene at the price tag of approximately $74B with a 58.6% premium paid by BMS over Celgene’s share price at time of acquisition. We have analyzed the deal to answer the question: Was it worth it? Read more to find out!...
Read More

Copay Accumulators & Maximizers

This whitepaper outlines how copay cards were intended to address patient affordability concerns and how copay accumulators and maximizers impact that process. However, there are steps brand leaders can take to reduce exposure to these programs....
Read More

Digital Health in Pharma

Consumers are now demanding the same access to personalized healthcare information and products they have grown accustomed to with their consumer goods. While some pharmaceutical companies are adapting, many find themselves struggling to evolve....
Read More

IO Landscape

IO Landscape Over 50,000 cancer patients needed for IO trials, but will it make a dent?We are in the midst of an explosion of clinical targets within the immuno-oncology field which has resulted in impactful advancements in cancer care. ...
Read More